4380-55-6

Basic information

• Product Name: Deltacortinene Acetate (Predisolone Acetate IMpurity)
• Synonyms: Deltacortinene Acetate (Predisolone Acetate IMpurity);Deltacortinene Acetate;Prednisolone Acetate EP Impurity E;2-((8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
• CAS NO: 4380-55-6
• Molecular Formula: C₂₃H₂₈O₅
• Molecular Weight: 384.46542
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals, Steroids
• Mol File: 4380-55-6.mol

Chemical Properties

• Melting Point: 222-223 °C
• Boiling Point: 556.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.25±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 12.46±0.60(Predicted)
• CAS DataBase Reference: Deltacortinene Acetate (Predisolone Acetate IMpurity)(CAS DataBase Reference)
• NIST Chemistry Reference: Deltacortinene Acetate (Predisolone Acetate IMpurity)(4380-55-6)
• EPA Substance Registry System: Deltacortinene Acetate (Predisolone Acetate IMpurity)(4380-55-6)

Safety Data

• Hazardous Substances Data: 4380-55-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Deltacortinene Acetate (Predisolone Acetate IMpurity) is used as a pharmaceutical compound for its anti-inflammatory and immunosuppressive properties. It helps in managing various conditions such as allergies, asthma, and autoimmune diseases by reducing inflammation and suppressing the immune system.
Used in Medical Treatments:
Deltacortinene Acetate (Predisolone Acetate IMpurity) is used as a treatment for various medical conditions, including rheumatoid arthritis, lupus, and other autoimmune disorders. Its anti-inflammatory and immunosuppressive effects make it a valuable component in the management of these conditions.
Used in Topical Applications:
Deltacortinene Acetate (Predisolone Acetate IMpurity) is used in topical formulations, such as creams and ointments, for the treatment of skin conditions like eczema, dermatitis, and psoriasis. Its anti-inflammatory properties help to reduce redness, swelling, and itching associated with these skin conditions.
Used in Ophthalmic Applications:
Deltacortinene Acetate (Predisolone Acetate IMpurity) is used in ophthalmic formulations, such as eye drops, for the treatment of eye conditions like uveitis and other inflammatory eye disorders. Its anti-inflammatory properties help to reduce inflammation and alleviate symptoms in the eye.

Upstream product

• 7753-60-8 anecortave 
• 52-21-1 prednisolone 21-acetate 
• 898-84-0 (8S,9S,10R,11S,13S,14S)-11-Hydroxy-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-6H-cyclopenta[a]phenanthrene-3,17-dione 

Downstream Products

• 13649-57-5 21-Deacetyldeflazacort 
• 14484-47-0 deflazacort 
• 52-21-1 prednisolone 21-acetate 
• 50-24-8 prednisolon 
• 52-70-0 21-acetoxy-6α,9-difluoro-11β,17-dihydroxy-pregna-1,4-diene-3,20-dione 
• 67-73-2 fluocinolone Acetonide 
• 356-12-7 fluocinonide 
• 4306-83-6 21-acetyloxy-11β,16α,17α-trihydroxy-6α,9α-difluoro-1,4-diene-3,20-dione 
• 2326-26-3 acetic acid 2-((6S,8S,9R,10S,11S,13S,14S)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15-decahydro-3H-cyclopenta[a]phenanthrene-17-yl)-2-oxo-ethyl ester 
• 72498-89-6 17α, 21-diacetyloxy-9β,11β-epoxy-6α-fluoro-1,4-diene-3,20-dione 
• 38680-83-0 21-acetyloxy-9β,11β-epoxy-17α-hydroxy-1,4-diene-3,20-dione 
• 37413-91-5 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 
• 38680-83-0 21-acetoxy-9,11β-epoxy-17-hydroxy-9β-pregna-1,4-diene-3,20-dione 
• 382-66-1 9-fluoro-11β,17-dihydroxy-21-methanesulfonyloxy-pregna-1,4-diene-3,20-dione 

Relevant articles and documents

Optimization of the synthesis of a key intermediate for the preparation of glucocorticoids

A short and efficient synthesis, based on a one-step double elimination, of a key intermediate in the synthesis of various glucocorticosteroids has been developed. This method can be carried out on large scale for further industrial applications. The synthesis allowed us to identify a novel prednisolone derivative 10 and its anti-inflammatory activity was determined in an in vivo model of inflammation. In order to understand the regioselectivity of the double elimination under various conditions, mechanistic studies were undertaken and confirmed the experimental results. We also propose a mechanism for the formation of the new steroid 10 studied by molecular modeling.

Preparation method of deflazacort

The present invention relates to a preparation method of deflazacort. The deflazacort is prepared through the following thirteen chemical synthesis reactions of elimination, cyanohydrintion, silanization, translocation and esterification, elimination, epoxidation, protection, ammoniation, cyclization, hydrolysis, bromo hydroxylation, debromination, esterification and the like. Raw materials for the preparation method of deflazacort are easily obtained. Meanwhile, the preparation method of deflazacort is mild in reaction condition, simple in process route and low in pollution, thus having a good application prospect.

Microbial conversion of pregna-4,9(11)-diene-17α,21-diol-3,20-dione acetates by Nocardioides simplex VKM Ac-2033D

The conversion of pregna-4,9(11)-diene-17α,21-diol-3,20-dione 21-acetate (I) and 17,21-diacetate (VI) by Nocardioides simplex VKM Ac-2033D was studied. The major metabolites formed from I were identified as pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate (II) and pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione (IV). Pregna-4,9(11)-diene-17α,21-diol-3,20-dione (III) and pregna-1,4,9(11)-triene-17α,20β,21-triol-3-one (V) were formed in minorities. Biotransformation products formed from VI were pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 17,21-diacetate (VII), pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate (II), pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione (IV), pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 17-acetate (VIII), pregna-1,4,9(11)-triene-17α,20β,21-triol-3-one (V). The conversion pathways were proposed including 1(2)-dehydrogenation, deacetylation, 20β-reduction and non-enzymatic migration of acyl group from position 17 to 21. The conditions providing predominant accumulation of pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate (II) from I and pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 17-acetate (VIII) from VI in a short-term biotransformation were determined.